By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Hutchison China MediTech (Chi-Med) 

21st Floor, Hutchison House
10 Harcourt Road
Hong Kong      China
Phone: 852-2121-8200 Fax: 852-2121-8281


SEARCH JOBS


Industry
Pharmaceutical






Company News
Hutchison China MediTech (Chi-Med) Files New Prospectus For $100 Million U.S. IPO 2/12/2016 12:21:48 PM
Hutchison China MediTech (Chi-Med) Initiates HMPL-523 Phase I Clinical Trial In Hematological Cancer In Australia 1/15/2016 9:19:59 AM
Hutchison China MediTech (Chi-Med) Release: Initiation Of Sulfatinib Phase III Registration Study In Neuroendocrine Tumor Patients 12/18/2015 6:22:07 AM
Hutchison China MediTech (Chi-Med) Relelase: US$105 Million Shanghai Land Compensation Agreement 12/9/2015 8:57:09 AM
Hutchison China MediTech (Chi-Med) Release: Initiation Of Fruquintinib Phase III Registration Trial In Non-Small Cell Lung Cancer 12/8/2015 11:42:51 AM
Hutchison China MediTech (Chi-Med) Initiates Sulfatinib U.S. Clinical Trials 11/6/2015 6:16:08 AM
Hutchison China MediTech (Chi-Med) Release: Completion Of Phase I Clinical Trial Of Novel Syk Inhibitor HMPL-523 For Autoimmune Diseases In Healthy Volunteers 10/30/2015 6:18:52 AM
Hutchison China MediTech (Chi-Med) Release: Sulfatinib Clinical Results And Fruquintinib-Savolitinib Combination Preclinical Results To Be Presented At The 2015 AACR-National Cancer Institute-EORTC Molecular Targets And Cancer Therapeutics Conference 10/30/2015 6:16:49 AM
Hutchison China MediTech (Chi-Med) Release: Proof-Of-Concept Study Of Fruquintinib In Non-Small Cell Lung Cancer Triggers Milestone Payment 10/23/2015 11:49:45 AM
Hutchison China MediTech (Chi-Med) Files For US NASDAQ IPO 10/19/2015 10:35:51 AM
123
//-->